| Literature DB >> 35519900 |
Longfei Lin1, Liyu Luo2, Ming Zhong3, Tanggui Xie3, Yuling Liu1, Hui Li1, Jian Ni4.
Abstract
Traditional Herbal Medicine (THM) has been used for thousands of years, and is popular worldwide due to its effectiveness in a variety of diseases. THM has also formed the basis of the discovery of modern drugs like artemisinin and paclitaxel. However, at present, studies that focus on development in the field of THM are stagnant because currently, the effective ingredients in the herbal formulations and the ambiguity of the underlying mechanisms of action are unknown. In this review, we have investigated the studies available that focused on the efficacy, active ingredients and bioavailability of THM, and the function of gut microbiota in THM-mediated treatment of disease. We hypothesized that most THMs treat diseases via three mechanisms: (1) metabolizing into active metabolites by the action of gut microbiota, (2) regulation of gut microbiota balance, and (3) regulating the fermentation products of the gut microbes. Therefore, focusing on these aspects can help elucidate the pharmacodynamic constituents of THM preparations, and their therapeutic mechanisms of action. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35519900 PMCID: PMC9064575 DOI: 10.1039/c9ra01838g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Chemical markers shared by various herbal medicines in the Chinese Pharmacopoeia 2015 edition
| Traditional herbal medicine | Dosage per day | Quality indicator component | Content limit ≥ |
|---|---|---|---|
| Radix ginseng | 3–9 g | Ginsenoside Rb1 | 0.18% |
| Ginsenoside Rg1, Ginsenoside Re | Sum 0.27% | ||
|
| 2–6 g | Schisandrin | 0.40% |
| Plantaginis semen | 9–15 g | Geniposide acid | 0.40% |
| Verbascoside | 0.30% | ||
| Radix scrophulariae | 9–15 g | Harpagide, harpagoside | Sum 0.45% |
| Cassiae semen | 9–15 g | Chrysophanol | 0.12% |
| Aurantio-obtusin | 0.080% | ||
| Radix saposhnikovia | 5–10 g | Prim- | Sum 0.24% |
| Forsythiae fructus | 6–15 g | Forsythin | 0.15% |
| Forsythoside A | 0.25% | ||
|
| 9–30 g | Chlorogenic acid | 0.070% |
| Loganin | 0.10% | ||
| Cacumen platycladi | 6–12 g | Quercetin | 0.10% |
| Radix rubiae | 6–10 g | Rubimaillin | 0.20% |
| Purpurin | 0.080% | ||
|
| 3–10 g | Curcumin | 0.90% |
| Radix astragali | 9–30 g | Astragaloside IV | 0.040% |
| Genistein glucose | 0.020% |
Chemical markers shared by various patent herbal medicine in the Chinese Pharmacopoeia 2015 edition
| Name | Indication | Specification | Dosage | Quality indicator component | Content limit ≥ |
|---|---|---|---|---|---|
| Ganmao Qingre granules | Colds, fever, cough, and pharyngalgia | 12 g per pouch | Once pouch and twice a day | Puerarin | 10 mg per pouch |
| Huoxiang Zhengqi water | Heatstroke, gastrointestinal cold | 10 mL per bottle | 5–10 mL per time and twice a day | Hesperidin | 0.18 mg mL |
| Niuhuang Shangqing tablets | Headache, dizziness, sore throats, aphtha, swollen gums, constipation | 0.265 g per tablets | 4 Tablets per time, two times a day | Baicalin | 1.1 mg per tablet |
| Jasminoidin | 0.45 mg per tablet | ||||
| Weikang Ling capsules | Acute and chronic gastritis, duodenal ulcer, gastrohelcosis, gastrorrhagia | 0.4 g per capsule | 4 Capsules and three times a day | Paeoniflorin | 1.0 mg per capsule |
| Hugan tablets | Chronic hepatitis and early cirrhosis, reduced aminotransferase | 0.36 g per tablet | 4 Tablets per time, 3 times a day | Schisandrin | 0.28 mg per tablet |
| Lidan Paishi granules | Cholecystitis, gallstone | 3 g per pouch | Removing urinary calculus: two pouchs per time, twice a day; diminish inflammation: one pouch per time, twice a day | Emodin | 3.0 mg per pouch |
| Fufang Danshen tablets | Coronary disease, angina pectoris | (1) 0.32 g per tablet | 3 Tablets (1, 2) or 1 tablet (3) per time, 3 times a day | Ginsenoside Rg1, Rb1, Re, and notoginsenoside R1 | (1, 2): Sum 6.0 mg per tablet |
| (2) Sugar-coated tablet | (3): Sum 18.0 mg per tablet | ||||
| (3) 0.8 g per tablet |
Pharmacokinetic research of THM in the clinica
| Medicinal | Dosage | Samples | Target compound | Contents in extract or dosage |
|
|
| AUC (ng h mL−1) |
|---|---|---|---|---|---|---|---|---|
| Rhei undulati rhizoma | 100 mg kg−1 | 12 Healthy volunteers (9 men/3 women | Rhein | 3.3759 ± 0.335 | 9746.689 ± 1011.72 | |||
| Rhubarb | 50 mg kg−1 | Eight male volunteers | Rhein | 12.308 mg g−1 | 59.69 ± 28.63 min | 2.79 ± 1.02 μg mL | 199.66 ± 63.50 min | 18.64 ± 5.67 μg |
| Milk thistle ( | 600 mg milk thistle extracts | 3 Healthy volunteers | Silychristin | 22.8% | 3.7 ± 0.6 h | 37 ± 7.8 | 7.9 ± 1.7 | 401 ± 93 |
| Silydianin | 8.93% | 2.8 ± 1.3 | 21 ± 3.1 | 3.3 ± 0.6 | 140 ± 47 | |||
| Silybin A | 22.0% | 1.0 ± 0.4 | 23 ± 7.9 | 1.3 ± 0.5 | 63 ± 38 | |||
| Silybin B | 34.0% | 1.3 ± 0.3 | 131 ± 28 | 3.4 ± 0.8 | 647 ± 234 | |||
| Isosilybin A | 8.59% | 1.7 ± 0.3 | 113 ± 30 | 4.1 ± 1.3 | 799 ± 403 | |||
| Isosilybin B | 3.67% | 1.5 ± 0.0 | 59 ± 16 | 4.0 ± 1.1 | 383 ± 195 | |||
| Artichoke leaf extracts | 2.4 g | 14 Healthy volunteers | Caffeic acid | 107.0 mg | 0.83 ± 0.3 | 6.51 ± 1.89 | 3.08 ± 1.53 | 23.02 ± 7.15 |
| 0.625 g | 14 Healthy volunteers | Caffeic acid | 153.8 mg | 0.94 ± 0.47 | 8.04 ± 2.64 | 2.69 ± 1.80 | 26.32 ± 10.69 | |
| Geriaforce™ tincture | 90 drops, 2.73 mL | 6 Healthy volunteers | Bilobalide | 646.93 μg | 1.09 ± 0.46 | 6.17 ± 5.67 | 2.33 ± 1.04 | 26.53 ± 26 |
| Ginkgolide A | 298.14 μg | 0.92 ± 0.38 | 3.81 ± 0.96 | 2.31 ± 0.66 | 12.42 ± 5.27 | |||
| Ginkgolide B | 147.45 μg | 0.88 ± 0.38 | 1.45 ± 0.98 | 2.34 ± 0.81 | 6.17 ± 3.77 | |||
| Ginkgo fresh plant extract tablets | 4 Tablets | 6 Healthy volunteers | Bilobalide | 1974.96 μg | 0.88 ± 0.3 | 11.6 ± 3.77 | 2.52 ± 1.7 | 41.56 ± 31.94 |
| Ginkgolide A | 881.52 μg | 0.80 ± 0.34 | 7.27 ± 3.83 | 2.66 ± 2.05 | 29.75 ± 29.64 | |||
| Ginkgolide B | 524.56 μg | 2.35 ± 2.27 | 4.61 ± 2.87 | 4.01 ± 2.58 | 43.48 ± 27.64 | |||
| EGb 761™ | 3 Tablets | 6 Healthy volunteers | Bilobalide | 3672.39 μg | 1.06 ± 0.4 | 29.87 ± 18.42 | 2.08 ± 0.23 | 100.57 ± 38.91 |
| Ginkgolide A | 1571.37 μg | 0.93 ± 0.43 | 16.97 ± 5.79 | 3.6 ± 2.96 | 80.83 ± 57.47 | |||
| Ginkgolide B | 836.46 μg | 2.0 ± 1.63 | 10.9 ± 5.59 | 3.94 ± 1.42 | 71.73 ± 26.98 | |||
| Cardiotonic pills | 30 Pills | 6 Male healthy volunteers | Tanshinol | 160 μg per pill | 1.33 ± 0.52 | 19.3 ± 5.1 ng | 1.16 ± 0.42 | 48.5 ± 3.4 |
| 6 Female healthy volunteers | Tanshinol | 160 μg per pill | 1.17 ± 0.68 | 31.3 ± 10.6 | 1.27 ± 0.21 | 77.6 ± 31.6 | ||
| Safflower oral solution | Single dose | 12 Healthy volunteers | Hydroxysafflor yellow A | 140 mg | 1 h | 73.5 ± 8.7 | 2.6–3.5 | |
| American ginseng powder | 10 g | 6 Healthy volunteers | Ginsenoside Rb1 | 31.7 mg g−1 | 4 h | 19.90 ± 5.43 | 155.0 ± 19.5 |
“Tmax”: peak time of component concentration in vivo; “Cmax”: maximum concentration; “T1/2”: eliminate half-time; “AUC”: area under the curve.
Fig. 1The metabolism pathways of sennoside A (A) and ginsenoside Re (B) by gut microbiota.
Changes in gut microbiota associated with disease
| Body system | Disease | Related gut microbiota | References |
|---|---|---|---|
| Metabolic system | Hepatocirrhosis |
|
|
| Liver cancer |
|
| |
| Type 2 diabetes |
|
| |
| NAFLD | Lachnospiraceae bacterium 609, |
| |
| Obesity |
|
| |
| Alimentary system | Diarrhea |
|
|
| Irritable bowel syndrome |
|
| |
| Inflammatory bowel disease |
|
| |
| Colorectal cancer |
|
| |
| Paradentitis |
|
| |
| Immune system | Rheumatic arthritis |
|
|
| Systemic lupus erythematosus | Enterobacteriaceae, Firmicutes/Bacteroidetes |
| |
| Respiratory system | Asthma |
|
|
| Chronic bronchitis |
|
| |
| Circulatory system | Atherosclerosis |
|
|
| Hyperlipemia |
|
| |
| Hypertension |
|
| |
| Nervous system | Depression | Spore-forming bacteria |
|
| Anxiety neurosis |
|
| |
| Autism |
|
| |
| Parkinson's disease | Enterobacteriaceae, |
| |
| Multiple sclerosis |
|
| |
| Alcohol dependence |
|
|
Pharmacodynamics of prototype compounds in THM and its metabolites in the gut
| Prototype compounds in THM | Metabolites in gut | The efficacy of metabolites superior to prototypes |
|---|---|---|
| Ginsenosides/ginsenoside Re | Compound K/ginsenoside Rh1 | Hepato-protective, anti-cancer, anti-wrinkling, and anti-aging properties/estrogenic effect |
| Glycyrrhizin | Glycyrrhetic acid | Anti-hepatotoxicity |
| Lancemaside A | Echinocystic acid | Anti-inflammatory, anti-tumor and anti-Alzheimer's disease |
| Baicalin | Baicalein, orohylin A | Anti-histamine-induced pruritus response |
| Poncirin | Ponciretin | Anti-inflammatory |
| Sennosides | Rheinanthrone | Diarrheal and laxative effect |
| Barbaloin | Aloe-rheinanthrone | Diarrheal effect |
| Rhapontin | Rhapontigenin | Antithrombotic and anti-allergic effects |
| Geniposide | Genipin | Cholagogue effects |
Fig. 2The treating diseases mechanisms of THM acting via gut microbiota: (1) metabolizing into active metabolites by the action of gut microbiota; (2) regulation of gut microbiota balance; (3) regulating the fermentation products of the gut microbes.